Skip to content

Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage

Comparison of Letrozole With Misoprostol Versus Misoprostol Alone in the Management of Missed Miscarriages

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07160855
Enrollment
92
Registered
2025-09-08
Start date
2025-05-13
Completion date
2025-11-12
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Miscarriage in First Trimester, Missed Miscarriage

Keywords

Abortion, missed, Abortion, induced, Letrozole, Misoprostol, first trimester

Brief summary

The goal of this clinical trial is to learn whether adding the medicine letrozole to Misoprostol helps women have a complete abortion more often than using Misoprostol alone for the treatment of missed miscarriage (when a pregnancy has stopped developing but has not yet passed naturally). The main questions this study aims to answer are: 1. Does taking letrozole for 3 days before misoprostol increase the chance of a complete abortion compared to misoprostol alone? 2. Does the use of letrozole affect the time it takes for abortion to occur? Who can Join? i. Women up to 13 weeks of pregnancy (based on last menstrual period and confirmed by ultrasound) who have a missed miscarriage. ii. Only those with a single pregnancy are eligible. iii. Women with a previous cesarean section or uterine scar are not included. What Will Happen in the Study A total of 92 women will take part. Participants will be randomly assigned to one of two groups: Group A: Letrozole tablets once daily for 3 days, followed by one dose of vaginal misoprostol. Group B: Placebo tablets for maximum of 3 days, followed by one dose of vaginal misoprostol. Doctors will monitor whether the abortion is complete within 24 hours. If it is not, other medical procedures will be offered as needed. Products of conception will be examined to confirm abortion.

Interventions

800 micrograms of a single dose of vaginal misoprostol will be given

10 mg oral letrozole for 3 days will be given

DRUGPlacebo

oral placebo for three days will be given

Sponsors

Nishtar Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women up till 13th weeks of gestation according to last menstrual period (LMP) dates, confirmed on ultrasound * Single intrauterine pregnancy * Planned for termination due to missed miscarriage

Exclusion criteria

* Previous history of cesarean section * Uterine scar due to previous procedure like myomectomy

Design outcomes

Primary

MeasureTime frameDescription
Complete abortionFrom start of study medication after randomization to within 24-hoursThe expulsion of both fetus and placenta without operative intervention and no retained products of conception confirmed on ultrasound.

Other

MeasureTime frameDescription
Induction-abortion intervalFrom start of study medication to abortion, within 24-hoursThe time interval (in hours) from the administration of first dose of Misoprostol up to the time when the fetus aborted.

Countries

Pakistan

Contacts

Primary ContactAfrayshum T Principal Investigator, MBBS
afrayshumtariq@gmail.com+92 3336239197

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026